From: Circ-SMARCA5 suppresses progression of multiple myeloma by targeting miR-767-5p
Items | Cox’s regression model | |||
---|---|---|---|---|
p value | HR | 95%CI | ||
Lower | Higher | |||
Univariate Cox’s regression | ||||
Circ-SMARCA5 (high vs low) | 0.001 | 0.259 | 0.119 | 0.565 |
Age (≥60 years vs < 60 years) | 0.545 | 1.238 | 0.620 | 2.472 |
Gender (male vs female) | 0.074 | 0.535 | 0.269 | 1.064 |
Immunoglobulin subtype | ||||
IgG vs others | 0.805 | 1.091 | 0.546 | 2.179 |
IgA vs others | 0.936 | 0.966 | 0.418 | 2.231 |
IgM vs others | 0.609 | 0.048 | 0.000 | 5345.739 |
IgD vs others | 0.837 | 1.233 | 0.168 | 9.065 |
Bence-Jones protein vs others | 0.959 | 0.977 | 0.403 | 2.369 |
Hb (≥10 g/dL vs < 10 g/dL) | 0.616 | 1.193 | 0.600 | 2.371 |
Calcium ≥11.5 mg/dL vs < 11.5 mg/dL) | 0.507 | 1.286 | 0.611 | 2.705 |
Scr (≥2 mg/dL vs < 2 mg/dL) | 0.858 | 1.085 | 0.445 | 2.645 |
ALB (≥3.5 mg/dL vs < 3.5 mg/dL) | 0.887 | 0.947 | 0.448 | 2.001 |
β2-MG (≥5.5 mg/L vs < 5.5 mg/L) | < 0.001 | 108.139 | 14.142 | 826.884 |
LDH (≥220 U/L vs < 220 U/L) | 0.385 | 1.370 | 0.673 | 2.789 |
Durie-Salmon stage (III vs I&II) | 0.287 | 1.465 | 0.725 | 2.959 |
ISS stage (III vs I&II) | < 0.001 | 108.139 | 14.142 | 826.884 |
Bone lesion (yes vs no) | 0.687 | 0.854 | 0.395 | 1.842 |
Cytogenetics abnormality | ||||
t (4; 14) translocation (yes vs no) | 0.747 | 0.822 | 0.250 | 2.706 |
t (14; 16) translocation (yes vs no) | 0.465 | 0.642 | 0.196 | 2.106 |
Del (17p) (yes vs no) | 0.575 | 1.314 | 0.506 | 3.408 |
Multivariate Cox’s regression with Forward Stepwise (Conditional) method | ||||
Circ-SMARCA5 (high vs low) | 0.038 | 0.345 | 0.127 | 0.941 |
Durie-Salmon stage (III vs I&II) | 0.015 | 2.586 | 1.206 | 5.546 |
ISS stage (III vs I&II) | < 0.001 | 148.290 | 17.354 | 1267.115 |